Risperidone for the treatment of cocaine dependence: Randomized, double- blind trial

John Grabowski, Howard Rhoades, Peter Silverman, Joy M. Schmitz, Angela Stotts, Dan Creson, Rahn Bailey

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

A partial blockade of the multiple actions of cocaine is one strategy by which cocaine dependence may be treated. Risperidone, a 5-hydroxytryptamine and dopamine D2 antagonist, is an atypical antipsychotic and was a candidate medication for the treatment of cocaine dependence. One hundred ninety-three cocaine-dependent subjects were enrolled in a 12-week, randomized, double- blind, placebo-controlled trial. Subjects initially received either placebo or 4 or 8 mg of risperidone, with a subsequent change to active doses of 2 mg and 4 mg. Subjects attended the clinic twice each week, provided urine samples, obtained medication, and underwent one behavioral therapy session per week. The study was terminated at the interim analysis. Retention was worse for the 4- and 8-mg active medication groups. Side effects were primarily associated with the 8-mg dose, although neither 2 mg nor 4 mg was well accepted by subjects. There was no reduction in cocaine use associated with risperidone. The results suggest that although antagonists might be a useful treatment approach, such as in the treatment of opiate dependence, risperidone is unlikely to find broad acceptance with the treatment-seeking population.

Original languageEnglish (US)
Pages (from-to)305-310
Number of pages6
JournalJournal of Clinical Psychopharmacology
Volume20
Issue number3
DOIs
StatePublished - Jun 1 2000

Fingerprint

Cocaine-Related Disorders
Risperidone
Cocaine
Placebos
Opioid-Related Disorders
Therapeutics
Antipsychotic Agents
Serotonin
Urine
Population

Cite this

Risperidone for the treatment of cocaine dependence : Randomized, double- blind trial. / Grabowski, John; Rhoades, Howard; Silverman, Peter; Schmitz, Joy M.; Stotts, Angela; Creson, Dan; Bailey, Rahn.

In: Journal of Clinical Psychopharmacology, Vol. 20, No. 3, 01.06.2000, p. 305-310.

Research output: Contribution to journalArticle

Grabowski, John ; Rhoades, Howard ; Silverman, Peter ; Schmitz, Joy M. ; Stotts, Angela ; Creson, Dan ; Bailey, Rahn. / Risperidone for the treatment of cocaine dependence : Randomized, double- blind trial. In: Journal of Clinical Psychopharmacology. 2000 ; Vol. 20, No. 3. pp. 305-310.
@article{d34202d80a56471284a30b5df8ab9b19,
title = "Risperidone for the treatment of cocaine dependence: Randomized, double- blind trial",
abstract = "A partial blockade of the multiple actions of cocaine is one strategy by which cocaine dependence may be treated. Risperidone, a 5-hydroxytryptamine and dopamine D2 antagonist, is an atypical antipsychotic and was a candidate medication for the treatment of cocaine dependence. One hundred ninety-three cocaine-dependent subjects were enrolled in a 12-week, randomized, double- blind, placebo-controlled trial. Subjects initially received either placebo or 4 or 8 mg of risperidone, with a subsequent change to active doses of 2 mg and 4 mg. Subjects attended the clinic twice each week, provided urine samples, obtained medication, and underwent one behavioral therapy session per week. The study was terminated at the interim analysis. Retention was worse for the 4- and 8-mg active medication groups. Side effects were primarily associated with the 8-mg dose, although neither 2 mg nor 4 mg was well accepted by subjects. There was no reduction in cocaine use associated with risperidone. The results suggest that although antagonists might be a useful treatment approach, such as in the treatment of opiate dependence, risperidone is unlikely to find broad acceptance with the treatment-seeking population.",
author = "John Grabowski and Howard Rhoades and Peter Silverman and Schmitz, {Joy M.} and Angela Stotts and Dan Creson and Rahn Bailey",
year = "2000",
month = "6",
day = "1",
doi = "10.1097/00004714-200006000-00003",
language = "English (US)",
volume = "20",
pages = "305--310",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Risperidone for the treatment of cocaine dependence

T2 - Randomized, double- blind trial

AU - Grabowski, John

AU - Rhoades, Howard

AU - Silverman, Peter

AU - Schmitz, Joy M.

AU - Stotts, Angela

AU - Creson, Dan

AU - Bailey, Rahn

PY - 2000/6/1

Y1 - 2000/6/1

N2 - A partial blockade of the multiple actions of cocaine is one strategy by which cocaine dependence may be treated. Risperidone, a 5-hydroxytryptamine and dopamine D2 antagonist, is an atypical antipsychotic and was a candidate medication for the treatment of cocaine dependence. One hundred ninety-three cocaine-dependent subjects were enrolled in a 12-week, randomized, double- blind, placebo-controlled trial. Subjects initially received either placebo or 4 or 8 mg of risperidone, with a subsequent change to active doses of 2 mg and 4 mg. Subjects attended the clinic twice each week, provided urine samples, obtained medication, and underwent one behavioral therapy session per week. The study was terminated at the interim analysis. Retention was worse for the 4- and 8-mg active medication groups. Side effects were primarily associated with the 8-mg dose, although neither 2 mg nor 4 mg was well accepted by subjects. There was no reduction in cocaine use associated with risperidone. The results suggest that although antagonists might be a useful treatment approach, such as in the treatment of opiate dependence, risperidone is unlikely to find broad acceptance with the treatment-seeking population.

AB - A partial blockade of the multiple actions of cocaine is one strategy by which cocaine dependence may be treated. Risperidone, a 5-hydroxytryptamine and dopamine D2 antagonist, is an atypical antipsychotic and was a candidate medication for the treatment of cocaine dependence. One hundred ninety-three cocaine-dependent subjects were enrolled in a 12-week, randomized, double- blind, placebo-controlled trial. Subjects initially received either placebo or 4 or 8 mg of risperidone, with a subsequent change to active doses of 2 mg and 4 mg. Subjects attended the clinic twice each week, provided urine samples, obtained medication, and underwent one behavioral therapy session per week. The study was terminated at the interim analysis. Retention was worse for the 4- and 8-mg active medication groups. Side effects were primarily associated with the 8-mg dose, although neither 2 mg nor 4 mg was well accepted by subjects. There was no reduction in cocaine use associated with risperidone. The results suggest that although antagonists might be a useful treatment approach, such as in the treatment of opiate dependence, risperidone is unlikely to find broad acceptance with the treatment-seeking population.

UR - http://www.scopus.com/inward/record.url?scp=0034073358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034073358&partnerID=8YFLogxK

U2 - 10.1097/00004714-200006000-00003

DO - 10.1097/00004714-200006000-00003

M3 - Article

C2 - 10831016

AN - SCOPUS:0034073358

VL - 20

SP - 305

EP - 310

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 3

ER -